Edoxaban: a focused review of its clinical pharmacology

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

(2013) Jeanne Mendell et al.   American Journal of Cardiovascular Drugs

Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations)

(2013) Jeffrey L. Anderson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials

(2013) G. Raskob et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

(2013) Genmin Lu et al.   NATURE MEDICINE

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

General mechanisms of coagulation and targets of anticoagulants (Section I)

(2013) Steen Husted et al.   THROMBOSIS AND HAEMOSTASIS

Antithrombotic Therapy for VTE Disease

(2012) Clive Kearon et al.   CHEST

Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation

(2012) Takeshi Yamashita et al.   CIRCULATION JOURNAL

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPEAN HEART JOURNAL

Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats

(2012) Taketoshi Furugohri et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

(2012) Jeanne Mendell et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

(2012) Gregory Y. H. Lip et al.   THROMBOSIS AND HAEMOSTASIS

Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor

(2012) A. G. G. Turpie et al.   THROMBOSIS AND HAEMOSTASIS

Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects

(2012) Nobuko Matsushima et al.   THROMBOSIS AND HAEMOSTASIS

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

(2012) Jeanne Mendell et al.   THROMBOSIS AND HAEMOSTASIS

Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats

(2012) Yoshiyuki Morishima et al.   THROMBOSIS RESEARCH

The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats

(2012) Yoshiyuki Morishima et al.   THROMBOSIS RESEARCH

Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates

(2011) Naoki Tsuji et al.   THROMBOSIS AND HAEMOSTASIS

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

(2011) Meyer Samama et al.   THROMBOSIS AND HAEMOSTASIS

Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system

(2011) Nobutoshi Sugiyama et al.   THROMBOSIS AND HAEMOSTASIS

Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

(2011) Toshio Fukuda et al.   THROMBOSIS AND HAEMOSTASIS

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux

(2011) Meyer Michel Samama et al.   THROMBOSIS RESEARCH

Tranexamic Acid for Trauma Patients: A Critical Review of the Literature

(2011) Andrew P. Cap et al.   JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

(2010) Christian T. Ruff et al.   AMERICAN HEART JOURNAL

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

(2010) Koichiro Ogata et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

(2010) Jeanne Mendell et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial

(2010)   LANCET

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

(2010) Stuart Connolly et al.   THROMBOSIS AND HAEMOSTASIS

Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation

(2010) Hui-Kyung Jeon et al.   THROMBOSIS AND HAEMOSTASIS

Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults

(2010) Meyer M. Samama et al.   THROMBOSIS RESEARCH

Guidelines on the diagnosis and management of acute pulmonary embolism

(2008) et al.   EUROPEAN HEART JOURNAL